BRPI0516609A - composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto - Google Patents
composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BRPI0516609A BRPI0516609A BRPI0516609-8A BRPI0516609A BRPI0516609A BR PI0516609 A BRPI0516609 A BR PI0516609A BR PI0516609 A BRPI0516609 A BR PI0516609A BR PI0516609 A BRPI0516609 A BR PI0516609A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- stereoisomer
- hydrate
- salt
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61901004P | 2004-10-18 | 2004-10-18 | |
| PCT/US2005/037374 WO2006044860A2 (en) | 2004-10-18 | 2005-10-18 | Thiadiazole compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516609A true BRPI0516609A (pt) | 2008-04-29 |
Family
ID=36203652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516609-8A BRPI0516609A (pt) | 2004-10-18 | 2005-10-18 | composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7354944B2 (enExample) |
| EP (1) | EP1809282B1 (enExample) |
| JP (1) | JP4931823B2 (enExample) |
| KR (1) | KR20070073791A (enExample) |
| CN (1) | CN101389335A (enExample) |
| AU (1) | AU2005295441B2 (enExample) |
| BR (1) | BRPI0516609A (enExample) |
| CA (1) | CA2583217C (enExample) |
| EA (1) | EA012181B1 (enExample) |
| ES (1) | ES2400689T3 (enExample) |
| IL (1) | IL182203A0 (enExample) |
| MA (1) | MA29029B1 (enExample) |
| MX (1) | MX2007004551A (enExample) |
| WO (1) | WO2006044860A2 (enExample) |
| ZA (1) | ZA200703975B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007004551A (es) | 2004-10-18 | 2007-05-23 | Amgen Inc | Compuestos tiadiazol y metodos de uso. |
| WO2007007054A1 (en) * | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| DE102006030479A1 (de) * | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| WO2008016123A1 (en) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| AU2008276521B2 (en) * | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| AU2008276512A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| US20110263647A1 (en) * | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| EP2958902B1 (en) | 2013-02-19 | 2017-11-15 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| MX2020011652A (es) | 2013-07-31 | 2022-09-27 | Novartis Ag | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. |
| PT3068393T (pt) | 2013-11-11 | 2022-06-14 | Amgen Inc | Terapia de combinação, incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros |
| ES2666130T3 (es) | 2013-12-19 | 2018-05-03 | Idorsia Pharmaceuticals Ltd | Derivados antibacterianos de 1H-indazol y 1H-indol |
| RU2624857C1 (ru) * | 2016-01-26 | 2017-07-07 | федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) | Фармацевтическая композиция с противогрибковой активностью и способ ее получения |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3127373A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| KR20210135241A (ko) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| KR20210135507A (ko) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CA3225293A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3842174A (en) * | 1966-12-23 | 1974-10-15 | American Cyanamid Co | Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents |
| US3991200A (en) * | 1974-04-25 | 1976-11-09 | American Cyanamid Company | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds |
| US3452035A (en) * | 1966-12-23 | 1969-06-24 | American Cyanamid Co | 2 - amino - 5 - (5 - nitro - 1 - substituted-2 - imidazolyl) - 1,3,4 - thiadiazoles and oxadiazoles |
| US3904756A (en) * | 1966-12-23 | 1975-09-09 | American Cyanamid Co | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds |
| US3666860A (en) | 1966-12-23 | 1972-05-30 | Gerald Berkelhammer | Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents |
| US3740434A (en) * | 1966-12-23 | 1973-06-19 | American Cyanamid Co | Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents |
| US3830924A (en) * | 1966-12-23 | 1974-08-20 | American Cyanamid Co | Substituted nitroimidazolyl-thiadiazoles as growth promoting agents |
| US3666830A (en) * | 1971-01-21 | 1972-05-30 | Gen Electric | Lead compound catalyzed siloxane resin system |
| US4086238A (en) * | 1976-06-21 | 1978-04-25 | Velsicol Chemical Corporation | 1-Thiadiazolyl-4-methoxymethyl-5-hydroxyimidazolidinones |
| DE2640601C2 (de) * | 1976-09-09 | 1985-11-28 | Agfa-Gevaert Ag, 5090 Leverkusen | Farbphotographisches Material mit 2-Äquivalent-Gelbkupplern |
| DE3407505A1 (de) | 1984-03-01 | 1985-09-05 | A. Nattermann & Cie GmbH, 5000 Köln | Neue benzothiazin-carbonsaeureamide mit antiarthritischer wirksamkeit |
| FR2572074B1 (fr) * | 1984-10-18 | 1987-07-17 | Sanofi Sa | Derives du thiadiazole actifs sur le systeme nerveux central, procede d'obtention et compositions pharmaceutiques les contenant |
| FR2636628B1 (fr) * | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
| WO1993019054A1 (en) | 1992-03-26 | 1993-09-30 | Dowelanco | N-heterocyclic nitro anilines as fungicides |
| JPH08151364A (ja) * | 1994-02-18 | 1996-06-11 | Nissan Chem Ind Ltd | 含窒素環状化合物および除草剤 |
| AU5845096A (en) | 1995-05-31 | 1996-12-18 | Nissan Chemical Industries Ltd. | 5-pyrazolecarboxamide derivatives and plant disease control agent |
| US20050053594A1 (en) * | 1995-11-16 | 2005-03-10 | Dario Alessi | RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK |
| EP0868195A2 (en) | 1995-12-20 | 1998-10-07 | Medical Research Council | Control of protein synthesis, and screening method for agents |
| AU1924099A (en) | 1997-12-18 | 1999-07-05 | Lyonnaise Industrielle Pharmaceutique (Lipha) | Piperazine derivatives useful as hypoglycemic agents |
| CA2315230C (en) * | 1998-01-09 | 2004-06-29 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Anti-cryptococcal peptides |
| US6323315B1 (en) * | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| AU2268401A (en) | 1999-12-17 | 2001-06-25 | Versicor Inc | Novel succinate compounds, compositions and methods of use and preparation |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| US6420400B1 (en) * | 2000-04-07 | 2002-07-16 | Kinetek Pharmaceuticals, Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| AR032653A1 (es) * | 2001-02-09 | 2003-11-19 | Telik Inc | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. |
| CA2442264A1 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | A method of treating cancer |
| FR2832713B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| WO2003084473A2 (en) | 2002-04-08 | 2003-10-16 | Merck & Co., Inc. | Method of treating cancer |
| EP1501829B1 (en) * | 2002-05-06 | 2010-11-24 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
| DK1506200T3 (da) | 2002-05-07 | 2007-04-10 | Neurosearch As | Diazabicykliske biarylderivater |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| DE60326894D1 (de) * | 2002-09-30 | 2009-05-07 | Neurosearch As | 1,4-Diazabicycloalkanderivate, deren Herstellung und Verwendung |
| EP1410844A1 (en) * | 2002-10-15 | 2004-04-21 | Centre National De La Recherche Scientifique (Cnrs) | Silicon-based porous catalytic system for oligomerising light olefins |
| EP1558607B1 (en) * | 2002-10-30 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| EP1622616B1 (en) | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2005014554A1 (en) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| ATE536353T1 (de) * | 2003-08-20 | 2011-12-15 | Vertex Pharma | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren |
| MXPA06001845A (es) * | 2003-08-21 | 2006-05-04 | Pfizer Prod Inc | Compuestos para el tratamiento de trastornos neurodegenerativos. |
| US20050143384A1 (en) * | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| JP2007510667A (ja) | 2003-11-07 | 2007-04-26 | スミスクライン ビーチャム （コーク） リミテッド | 癌の治療法 |
| AU2005223649A1 (en) | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| CA2571828A1 (en) * | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
| MX2007000615A (es) * | 2004-07-16 | 2007-03-07 | Janssen Pharmaceutica Nv | Compuestos dimericos de piperidina, piperazina o morfolina o sus analogos de 7 miembros adecuados para el tratamiento de trastornos neurodegenerativos. |
| MX2007004551A (es) * | 2004-10-18 | 2007-05-23 | Amgen Inc | Compuestos tiadiazol y metodos de uso. |
| CN101035792B (zh) | 2004-10-20 | 2010-09-15 | 神经研究公司 | 新颖的二氮杂双环芳基衍生物和它们的医药用途 |
| EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
-
2005
- 2005-10-18 MX MX2007004551A patent/MX2007004551A/es active IP Right Grant
- 2005-10-18 WO PCT/US2005/037374 patent/WO2006044860A2/en not_active Ceased
- 2005-10-18 AU AU2005295441A patent/AU2005295441B2/en not_active Ceased
- 2005-10-18 EP EP05812533A patent/EP1809282B1/en not_active Expired - Lifetime
- 2005-10-18 KR KR1020077008816A patent/KR20070073791A/ko not_active Ceased
- 2005-10-18 US US11/251,846 patent/US7354944B2/en not_active Expired - Lifetime
- 2005-10-18 ES ES05812533T patent/ES2400689T3/es not_active Expired - Lifetime
- 2005-10-18 BR BRPI0516609-8A patent/BRPI0516609A/pt not_active IP Right Cessation
- 2005-10-18 EA EA200700886A patent/EA012181B1/ru not_active IP Right Cessation
- 2005-10-18 JP JP2007537015A patent/JP4931823B2/ja not_active Expired - Fee Related
- 2005-10-18 CA CA2583217A patent/CA2583217C/en not_active Expired - Fee Related
- 2005-10-18 CN CNA2005800356937A patent/CN101389335A/zh active Pending
-
2007
- 2007-03-26 IL IL182203A patent/IL182203A0/en unknown
- 2007-05-16 ZA ZA200703975A patent/ZA200703975B/xx unknown
- 2007-05-17 MA MA29916A patent/MA29029B1/fr unknown
-
2008
- 2008-03-19 US US12/077,634 patent/US7700636B2/en active Active
- 2008-03-19 US US12/077,633 patent/US7919514B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20080255145A1 (en) | 2008-10-16 |
| EA012181B1 (ru) | 2009-08-28 |
| US20060154961A1 (en) | 2006-07-13 |
| US20080269243A1 (en) | 2008-10-30 |
| WO2006044860A2 (en) | 2006-04-27 |
| CA2583217A1 (en) | 2006-04-27 |
| US7700636B2 (en) | 2010-04-20 |
| ES2400689T3 (es) | 2013-04-11 |
| CA2583217C (en) | 2011-05-31 |
| US7919514B2 (en) | 2011-04-05 |
| AU2005295441A1 (en) | 2006-04-27 |
| CN101389335A (zh) | 2009-03-18 |
| MX2007004551A (es) | 2007-05-23 |
| ZA200703975B (en) | 2009-01-28 |
| EP1809282A4 (en) | 2009-11-25 |
| EA200700886A1 (ru) | 2008-02-28 |
| WO2006044860A3 (en) | 2007-07-05 |
| JP2008516986A (ja) | 2008-05-22 |
| EP1809282B1 (en) | 2013-01-09 |
| IL182203A0 (en) | 2007-07-24 |
| EP1809282A2 (en) | 2007-07-25 |
| JP4931823B2 (ja) | 2012-05-16 |
| MA29029B1 (fr) | 2007-11-01 |
| KR20070073791A (ko) | 2007-07-10 |
| US7354944B2 (en) | 2008-04-08 |
| AU2005295441B2 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0516609A (pt) | composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto | |
| BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
| BRPI0917540A2 (pt) | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável | |
| BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0720637A2 (pt) | Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto | |
| BRPI0822033A2 (pt) | Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| BRPI0508263B8 (pt) | derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
| BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
| BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| ITMI20031570A1 (it) | Composizione per uso dietetico, farmaceutico o cosmetico | |
| PT1701698E (pt) | Composição farmacêutica para a administração oral de cci-779 | |
| BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| IL182054A0 (en) | Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | |
| DE60336225D1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| BRPI0614730A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0806529A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
| BRPI0807867A2 (pt) | Derivado de indol ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um derivado de (indol-3-il) heterociclo, e, método de tratamento de dor | |
| BRPI0611025A2 (pt) | composto, uso de um composto, e, composição farmacêuticamente aceitável |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013. |